Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000447 · ClinicalTrials.gov registry record · Phase 4
Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch)
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT00000447 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 200 participants.
The verdict
NCT00000447, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
This study will develop a behavioral and drug relapse prevention program for individuals who are dependent on both alcohol and tobacco. The study's goal is to show that individuals receiving nicotine replacement therapy and naltrexone (Revia) with behavior therapy will have higher rates of abstinence from both smoking and drinking than individuals who do not receive the drug therapies. Individuals will be placed in a 12-week outpatient treatment program with followup assessments 1, 3, and 6 months after treatment.
Interventions
- DRUG naltrexone (Revia)
- DRUG nicotine replacement patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 1998-09 |
| Est. Completion | 2003-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000447
The ClinicalTrials.gov registry entry for NCT00000447 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which naltrexone (Revia) is the first listed.
NCT00000447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000447 about?
NCT00000447 is a clinical study titled "Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch)". This study will develop a behavioral and drug relapse prevention program for individuals who are dependent on both alcohol and tobacco. The study's goal is to show that individuals receiving nicotine replacement therapy and naltrexone (Revia) with behavior therapy will have higher rates of abstinenc...
What is the current status of trial NCT00000447?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 1998-09. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00000447?
The interventions under investigation include: naltrexone (Revia) (DRUG), nicotine replacement patch (DRUG).
Who is sponsoring clinical trial NCT00000447?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.